Skip to main content
SpringerLink
Log in

Outcomes Research in Cancer Clinical Trial Cooperative Groups: The RTOG Model

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Background: The Radiation Therapy Oncology Group (RTOG), a National Cancer Institute sponsored cancer clinical trials research cooperative, has recently formed an Outcomes Committee to assess a comprehensive array of clinical trial endpoints and factors impacting the net effect of therapy. Methods: To study outcomes in a consistent, comprehensive and coordinated manner, the RTOG Outcomes Committee developed a model to assess clinical, humanistic, and economic outcomes important in clinical trials. Results: This paper reviews how the RTOG incorporates outcomes research into cancer clinical trials, and demonstrates utilization of the RTOG Outcomes Model to test hypotheses related to non-small cell lung cancer (NSCLC). In this example, the clinical component of the model indicates that the addition of chemotherapy to radiotherapy (RT) improves survival but increases the risk of toxicity. The humanistic component indicates that esophagitis is the symptom impacting quality of life the greatest and may outweigh the benefits in elderly (≥70 years) patients. The economic component of the model indicates that accounting for quality-adjusted survival, concurrent chemoRT for the treatment of NSCLC is within the range of economically acceptable recommendations. Conclusion: The RTOG Outcomes Model guides a comprehensive program of research that systematically measures a triad of endpoints considered important to clinical trials research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mandelblatt JS, Eisenberg JM. Historical and methodological perspectives on cancer research. Oncology 1995; 9(Suppl 11): 23-32.

    Google Scholar 

  2. Lee SJ, Earle CC, Weeks JC. Outcomes research in oncology: History, conceptual framework, and trends in the literature. J Natl Cancer Inst 2000; 92(3): 195-204.

    Google Scholar 

  3. McCarthy T, White KL. Origins of health services research. Health Serv Res 2000; 35(2): 375-387.

    Google Scholar 

  4. Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966; 44(3): 166-206.

    Google Scholar 

  5. Hanks G, Coia L, Curry J. Patterns of care studies: Past, present, and future. Semin Radiat Oncol 1997; 7(2): 97-100.

    Google Scholar 

  6. Nattinger AB, Gottlieb MS, Veum J, et al. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 1992; 326(17): 1102-1127.

    Google Scholar 

  7. Lee-Feldstein A, Anton-Culver H, Feldstein PJ. Treatment differences and other prognostic factors related to breast cancer and survival: Delivery systems and medical outcomes. J Am Med Assoc 1994; 271(15): 1163-1168.

    Google Scholar 

  8. Newschaffer CJ, Penberthy L, Desch CE, et al. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996; 15685-15690.

  9. Harlan L, Brawley O, Pommerenke F, et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 1995; 1391-1105.

  10. Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 1995; 13235-13252.

  11. Guidry JJ, Aday LA, Zhang D, Winn RJ. Cost considerations as potential barriers to cancer treatment. Cancer Pract 1998; 6(3): 182-187.

    Google Scholar 

  12. Coyle YM. Developing theoretical constructs for outcomes research. Am J Med Sci 2000; 319(4): 245-249.

    Google Scholar 

  13. Agency for Health Care Policy and Research. Medical treatment effectiveness research. Rockville, MD: Agency for Health Care Policy and Research, 1990.

    Google Scholar 

  14. Rettig RA. Cancer Crusade: The Story of the National Cancer Act of 1971. Washington, DC: Joseph Henry Press, 1977.

    Google Scholar 

  15. Johnson JR, Temple R. Food and drug administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985; 69(10): 1155-1157.

    Google Scholar 

  16. Clinical Trials Cooperative Group Program. Cancer Therapy Evaluation Program: Guidelines. Bethesda, Maryland: Division of Cancer Treatment, National Cancer Institute, 1988.

    Google Scholar 

  17. Strain JJ. The evaluations of quality of life evaluations in cancer therapy. Oncology 1990; 4(5): 22-26.

    Google Scholar 

  18. Nayfield SG, Ganz PA, Moinpour CM, et al. Report from a National Cancer Institute (USA) workshop on quality of life in cancer clinical trials. Qual Life Res 1992; 1(3): 203-210.

    Google Scholar 

  19. Cella DF, Orofiamma B, Holland JC, et al. The relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. Cancer 1987; 60(7): 1661-1667.

    Google Scholar 

  20. Johnson DJ, Scott CB, Marks JE, et al. Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys 2002; 54(5): 1455-1459.

    Google Scholar 

  21. Moinpour CM, Sawyers Triplet J, McKnight B, et al. Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology 2000; 9(4): 340-354.

    Google Scholar 

  22. Moinpour CM, Lovato LC. Ensuring the quality of quality of life data: The Southwest Oncology Group experience. Stat Med 1998; 17(5-7): 641-651.

    Google Scholar 

  23. Hayden KA, Moinpour CM, Metch B, et al. Pitfalls in quality-of-life assessment: Lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum 1993; 20(9): 1415-1419.

    Google Scholar 

  24. Moinpour CM, Feigl P, Metch B, et al. Quality of life end points in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 1989; 81485-81495.

  25. Scott CB, Stetz J, Bruner DW, Wasserman TH. Radiation Therapy Oncology Group quality of life assessment: Design, analysis, and data management issues. Qual Life Res 1994; 3(3): 199-206.

    Google Scholar 

  26. Bruner DW. In search of the 'quality' in quality of life research [editorial]. Int J Radiat Oncol Biol Phys 1995; 31(1): 191-192.

    Google Scholar 

  27. Wasserman T, Bruner DW, Scott C. Radiation Therapy Oncology Group (RTOG). J Natl Cancer Inst Monogr 1996; 2081-2082.

  28. Bruner DW, Scott C, Lawton C, et al. RTOG's first quality of life study-RTOG 90-20: A phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33(4): 901-906.

    Google Scholar 

  29. Fisher J, Scott C, Stevens R, et al. Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13. Int J Radiat Oncol Biol Phys 2000; 48(5): 1307-1310.

    Google Scholar 

  30. Choucair AK, Scott C, Urtasun R, et al. Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14: Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1997; 38(1): 9-20.

    Google Scholar 

  31. Bailes JS. Cost aspects of palliative cancer care. Semin Oncol 1995; 22(2 Suppl 3): 64-66.

    Google Scholar 

  32. Office of Disease Prevention and Health Promotion. A framework for cost-utility analysis of government health care programs. Washington, DC (1992-617-025/68280): US Government Printing Office, 1992.

    Google Scholar 

  33. Jaakkimainen L, Goodwin PJ, Warde P, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized in nonsmall-cell lung cancer. J Clin Oncol 1990; 8(8): 1301-1309.

    Google Scholar 

  34. Tjan-Heijnen VC, Caleo S, Postmus PE, et al. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: An EORTC double-blind placebo-controlled phase III study (08923). Ann Oncol 2003; 14(2): 248-257.

    Google Scholar 

  35. Crott R, Neymark N. Health economics units achievement. Eur J Cancer 2002; 38(Suppl 4): S147-S150.

    Google Scholar 

  36. Neymark N, Adriaenssen I, Gorlia T, et al. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: Results decisively determined by the cut-o. time-point chosen for the analysis. Eur J Cancer 2001; 37(14): 1768-1774.

    Google Scholar 

  37. Neymark N, Adriaenssen I, Gorlia T, et al. Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 2002; 11(3): 233-248.

    Google Scholar 

  38. Neymark N, Adriaenssen I. The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur J Cancer 1999; 35(13): 1789-1795.

    Google Scholar 

  39. Neymark N, Kiebert W, Torfs K, et al. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: Report of a workshop. Eur J Cancer 1998; 9: 1317-1333.

    Google Scholar 

  40. Neymark N. Techniques for health economics anlaysis in oncology: Part 2. Crit Rev Oncol Hematol 1999; 30(1): 13-24.

    Google Scholar 

  41. Konski A, Bracy P, Weiss S, Grigsby P. Cost-utility analysis of a malignant glioma protocol. Int J Radiat Oncol Biol Phys 1997; 39(3): 575-578.

    Google Scholar 

  42. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a Phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 1996; 77(8): 1535-1543.

    Google Scholar 

  43. Murray KJ, Nelson DF, Scott C, et al. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: A report of Radiation Therapy Oncology Group (RTOG) 83-02. Int J Radiat Oncol Biol Phys 1995; 31(3): 453-459.

    Google Scholar 

  44. Owen JB, Grigsby PW, Caldwell TM, et al. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04. Int J Radiat Oncol Biol Phys 2001; 49(3): 633-639.

    Google Scholar 

  45. Watkins-Bruner D, Hanks GE. An outcomes-based management model of patient care. In: Haas M eds. Outcomes in Radiation Therapy: A Multidisciplinary Approach. Boston: Jones & Bartlett Publishers, 2001.

    Google Scholar 

  46. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996; 125(9): 723-729.

    Google Scholar 

  47. Pignon JP. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small-cell lung cancer: A meta-analysis. Cancer 1996; 77(11): 2413-2414.

    Google Scholar 

  48. Sause W, Scott C, Taylor S, et al. Phase II Trial of Combination Chemotherapy and Irradiation in Non-Small-Cell Lung Cancer, Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 1992; 15(2): 163-167.

    Google Scholar 

  49. Lee JS, Scott C, Komaki R, et al. Concurrent Chemoradiation Therapy with Oral Etoposide and Cisplatin for Locally Advanced Inoperable Non-Small Cell Lung Cancer: RTOG Protocol 91-06. J Clin Oncol 1996; 14(4): 1055-1064.

    Google Scholar 

  50. Byhardt R, Scott C, Ettinger D, et al. Concurrent hyperfractionated irradiation and hemotherapy for unresectable non-small cell lung cancer. Cancer 1995; 75(9): 2337-2344.

    Google Scholar 

  51. Komaki R, Scott C, Urtasun R, et al. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): Comparison of RTOG 83-11 to RTOG 91-06. Am J Clin Oncol 1997; 20(5): 435-440.

    Google Scholar 

  52. Cox J, Scott C, Byhardt R, et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small carcinoma of lung (NSSCCL): Analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1999; 43(3): 505-509.

    Google Scholar 

  53. Movsas B, Sause W, Byhardt R, et al. The Benefit of Treatment Intensification is Age and Histology-Dependent in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC): A Quality-Adjusted Survival Analysis of Radiation Therapy Oncology Group (RTOG) Chemo-Radiation Studies. Int J Radiat Oncol Biol Phys 1999; 45(5): 1143-1149.

    Google Scholar 

  54. Movsas B, Scott C, Sause W, et al. A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis: The Radiation Therapy Oncology Group (RTOG) Chemoradiation Studies for Locally Advanced Non-small Cell Lung cancer (LA-NSCLC) [Abstract]. London, UK: American Radium Society, 2000.

    Google Scholar 

  55. Gelber RD, Goldhirsch A, Cole BF. Evaluation of effectiveness: Q-TWiST. Cancer Treatment Rev 1993; 19(Suppl A): 73-84.

    Google Scholar 

  56. Morgan LC, Grayson D, Peters HE, et al. Lung Cancer in New South Wales: Current Trends and the Influence of Age and Sex. Med J Aust 2000; 172(12): 578-582.

    Google Scholar 

  57. Langer C, Scott C, Byhardt R, et al. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LA-NSCLC) [Abstract]. Lung Cancer 2000; 29(Suppl 1): 104.

    Google Scholar 

  58. Scott C, Sause W, Johnson D, et al. Factors which influence QOL in patients with non-small cell lung cancer (NSCLC): A RTOG Study (RTOG 89-01). Int J Radiat Oncol Biol Phys 1997; 39(2): 198.

    Google Scholar 

  59. Konski A, Scott C, Movsas B, et al. Cost-utility analysis of various treatments for non-small cell carcinoma of the lung [Abstract]. Eur J Cancer 2000; 36S19.

  60. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146(4): 473-481.

    Google Scholar 

  61. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.

    Google Scholar 

  62. Hillner BE, Smith TJ. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer. Semin Oncol 1996; 23 (2 Suppl 5): 25-30.

    Google Scholar 

  63. Movsas B, Scott C, Curran W, et al. A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proceedings of the American Society of Clinical Oncology. J Clin Oncol 2001; 20(1247): 313a.

  64. Groeger AM, Odocha O, Mueller MR, et al. Racial Variation in Lung Cancer. Anticancer Res 1997; 17(4A): 2843-2848.

    Google Scholar 

  65. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000; 48(5): 1475-1482.

    Google Scholar 

  66. Roach M, Winter K, Michalski J, et al. Mean dose of radiation to the bulb of the penis correlates with risk of impotence at 24 months: Preliminary analysis of Radiation Therapy Oncology Group (RTOG) phase I/II dose escalation trial 9406 [Abstract]. Int J Radiat Oncol Biol Phys 2000; 48(3): 316.

    Google Scholar 

  67. Kanouse DE, Kallich JD, Kahan JP. Dissemination of effectiveness and outcomes research. Health Policy 1995; 34(3): 167-192.

    Google Scholar 

  68. Naughton MJ, Herndon JE, Shumaker SA, et al. The health-related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033. Qual Life Res 2002; 11(3): 235-248.

    Google Scholar 

  69. Kornblith AB, Herndon 2nd JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B Study. J Clin Oncol 2002; 20(10): 2441-2452.

    Google Scholar 

  70. Kornblith AB, Herndon 2nd JE, Zuckerman E, et al. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study. Ann Oncol 2001; 12(5): 633-641.

    Google Scholar 

  71. Kornblith AB, Herndon 2nd JE, Zuckerman E, et al. Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer 2001; 91(2): 443-454.

    Google Scholar 

  72. Herndon 2nd JE, Fleishman S, Kornblith AB, et al. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 1999; 85(2): 333-340.

    Google Scholar 

  73. Kornblith AB, Herndon 2nd JE, Zuckerman E, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Ann Oncol 1998; 9(3): 297-306.

    Google Scholar 

  74. Hill JM, Kornblith AB, Jones D, et al. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 1998; 82(1): 208-218.

    Google Scholar 

  75. Tross S, Herndon 2nd JE, Korzun A, et al. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst 1996; 88(10): 661-667.

    Google Scholar 

  76. Kornblith AB, Hollis DR, Zuckerman E, et al. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol 1993; 11(11): 2081-2089.

    Google Scholar 

  77. Wadler S, Brain C, Catalono P, et al. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: Eastern Cooperative Oncology Group Study E6296. Cancer J 2002; 8(3): 282-286.

    Google Scholar 

  78. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94(3): 173-181.

    Google Scholar 

  79. Auchter RM, Scholtens D, Adak S, et al. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: Report of ECOG study 4593. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 2001; 50(5): 1199-1206.

    Google Scholar 

  80. Schink JC, Weller E, Harris LS, et al. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: An Eastern Cooperative Oncology Group Phase II Study (E2E93). Cancer J 2001; 7(2): 155-164.

    Google Scholar 

  81. Bonomi P, Kim K, Fairclough DL, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose level of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of the Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18(3): 623-631.

    Google Scholar 

  82. Fairclough DL, Fetting JH, Cella D, et al. Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 1999; 8(8): 723-731.

    Google Scholar 

  83. Finkelstein DM, Cassileth BR, Bonomi PD, et al. A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastic lung cancer patients. An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 1988; 11(6): 630-633.

    Google Scholar 

  84. Fossa SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 2003; 21(7): 1249-1254.

    Google Scholar 

  85. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001; 19(1): 62-71.

    Google Scholar 

  86. Curran D, van Dongen JP, Aaronson NK, et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: Results of EORTC trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast cancer Co-operative Group (BCCG). Eur J Cancer 1998; 34(3): 307-314.

    Google Scholar 

  87. Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The Europeon Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16(6): 2133-2141.

    Google Scholar 

  88. Curran D, Fossa S, Aaronson N, et al. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer 1997; 33(11): 1809-1814.

    Google Scholar 

  89. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1997; 33(11): 1752-1758.

    Google Scholar 

  90. da Silva FC, Fossa SD, Aaronson NK, et al. The quality of life patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853. Eur J Cancer 1996; 32A(1): 72-77.

    Google Scholar 

  91. Bezjak A, Dixon P, Brundgage M, et al. Radomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 2002; 54(3): 719-728.

    Google Scholar 

  92. Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxurbicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18(12): 2385-2394.

    Google Scholar 

  93. Kirkbride P, Bezjak A, Pater J, et al. Dexamethasone for the prophylaxis of radiation-induced emesis: A National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 2000; 18(9): 1960-1966.

    Google Scholar 

  94. Osoba D, Zee B, Warr D, et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Supportive Care Cancer 1997; 5(4): 307-313.

    Google Scholar 

  95. Pater JL, Zee B, Palmer M, et al. Fatigue in patients with cancer: Results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30. Supportive Care Cancer 1997; 5(5): 410-413.

    Google Scholar 

  96. Dancey J, Zee B, Osoba D, et al. Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 1997; 6(2): 151-158.

    Google Scholar 

  97. Moinpour CM, Lyons B, Grevstad PK, et al. Quality of life in advanced non-small-cell lung cancer: Results of a Southwest Oncology Group randomized trial. Qual Life Res 2002; 11(2): 115-126.

    Google Scholar 

  98. Kelly K, Crowley JJ, Bunn Jr PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer; A Southwest Oncology Group trial. J Clin Oncol 2001; 19(13): 3210-3218.

    Google Scholar 

  99. Moinpour CM, Lovato LC, Thompson Jr IM, et al. Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors. J Clin Oncol 2000; 18(9): 1942-1953.

    Google Scholar 

  100. Rubio-Terres C, Tisaire JL, Kobina S, Moyano A. Costminimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. Lung Cancer 2002; 35(1): 81-89.

    Google Scholar 

  101. Bennett CL, Stinson TJ, Yang T, Lurain JR. The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. Semin Oncol 1999; 26(1 Suppl 1): 50-45.

    Google Scholar 

  102. Hillner BE, Kirkwood JM, Atkins MB, et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. Cancer Invest 1997; 15(6): 2351-2358.

    Google Scholar 

  103. Neymark N. Techniques for health economics analysis in oncology: Part 1. Crit Rev Oncol Hematol 1999; 30(1): 1-11.

    Google Scholar 

  104. Williamson SK, Crowley JJ, Livingston RB, et al. Goodwin JW. Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. Invest New Drugs 1995; 13(1): 67-71.

    Google Scholar 

  105. Ramsey SD, Moinpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94(4): 291-297.

    Google Scholar 

  106. Bennett CL, Hynes D, Godwin J, et al. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial. Cancer Invest 2001; 19(6): 603-610.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Therapy Oncology Group, Philadelphia, PA, USA

    D.W. Bruner, B. Movsas, A. Konski, M. Roach, M. Bondy, C. Scarintino, C. Scott & W. Curran

Authors
  1. D.W. Bruner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Movsas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Konski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Roach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Bondy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Scarintino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruner, D., Movsas, B., Konski, A. et al. Outcomes Research in Cancer Clinical Trial Cooperative Groups: The RTOG Model. Qual Life Res 13, 1025–1041 (2004). https://doi.org/10.1023/B:QURE.0000031335.02254.3b

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:QURE.0000031335.02254.3b

Search

Navigation